טוען...
Cost-effectiveness of emicizumab for the treatment of hemophilia A: a systematic review
BackgroundEmicizumab, a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis of bleeding episodes in people with hemophilia A, can impose a significant financial burden. We conducted a systematic review to evaluate the reporting quality of existing pharmacoeconomic...
שמור ב:
| Main Authors: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2025-10-01
|
| סדרה: | Frontiers in Public Health |
| נושאים: | |
| גישה מקוונת: | https://www.frontiersin.org/articles/10.3389/fpubh.2025.1658760/full |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|